Company intelligence / Profile preview

Ventyx Biosciences

San Diego, California, United Statesventyxbio.com ↗

Ownership: Public · VTYX
Development stage: Phase 2

Overview

Ventyx has multiple programs in Phase 2 clinical trials. Their NLRP3 inhibitors VTX2735 and VTX3232 are in Phase 2 for recurrent pericarditis and neurodegenerative/cardiometabolic diseases respectively. Their inflammatory bowel disease portfolio includes tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor), both of which have completed Phase 2 clinical trials.

Therapeutic areas: GastroenterologyCardiovascularRheumatologyImmunologyDermatologyNeurology
Modalities: Small moleculesoral therapies
Industry: Biotech

Drug pipeline

7 assets

VTX3232

6 more assets in the full pipeline.

Request access →

Partnerships

Sanofi ($27 million strategic investment in September 2024)

Financials

Market cap: $1B
Total revenue: $0
Enterprise value: $821.9M

Beyond the preview

Go deeper on Ventyx Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ventyx Biosciences.

Explore the full profile